Nuance seeks China approval for Ohtuvayre following Phase III trial success
The company aims to submit an NDA to China’s NMPA in the second half of 2025.
Therapy Area
Abbott’s studies show CGM technology linked to lower heart hospitalisation risk
MSD’s Phase III trial of Keytruda meets endpoint for treating ovarian cancer
First subject dosed in Revolution Medicines’ Phase III NSCLC treatment trial
ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data
GSK to spend $2bn on Phase III liver disease drug acquisition
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK and iTeos drop anti-TIGIT drug following trial failure
